A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 1,301–1,400 of 3,965
Efficacy and Safety of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis
Yoon, H., Kim, D. S., & Song, J. W. (2018) · Respiration · doi:10.1159/000492937 · Cited by 29
Shao, R., Wang, F., Lyu, M., Yang, J., Zhang, P., & Zhu, Y. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00412 · Cited by 29
“, 2014), it was striking that only few molecules were shown to reduce disease progression of IPF except pirfenidone and nintedanib (King et al., 2014; Richeldi et al., 2014).”
BackgroundReal-world experiences: Efficacy and tolerability of pirfenidone in clinical practice
Fang, C., Huang, H. F., Guo, J., Ferianc, M., & Xu, Z. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228390 · Cited by 29
Pesonen, I., Carlson, L., Murgia, N., Kaarteenaho, R., Sköld, C. M., Myllärniemi, M., & Ferrara, G. (2018) · Multidisciplinary Respiratory Medicine · doi:10.1186/s40248-018-0126-7 · Cited by 25
Herink, M. C., Irwin, A. N., & Zumach, G. M. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2167 · Cited by 26
TGFβ1-RCN3-TGFBR1 loop facilitates pulmonary fibrosis by orchestrating fibroblast activation
Wu, M., Wang, Z., Shi, X., Zan, D., Chen, H., Yang, S., Ding, F., Liu, Y., Tan, P., Ma, R. Z., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02533-z · Cited by 28
Sabir, M. W., Farhan, M., Almalki, N. S., Alnfiai, M. M., & Sampedro, G. A. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1282200 · Cited by 30
Wang, B., Gao, Y., Sun, L., Xue, M., Wang, M., Zhang, Z., Zhang, L., & Zhang, H. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122404 · Cited by 32
Patient considerations and drug selection in the treatment of idiopathic pulmonary fibrosis
Hart, S. P., Trawinska, M., & Rupesinghe, R. (2016) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s81144 · Cited by 28
Clinical Features and Treatment of Scleroderma
Boin, F., & Wigley, F. M. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-1738-9.00084-0 · Cited by 29
Sailland, J., Grosche, A., Baumlin, N., Dennis, J. S., Schmid, A., Krick, S., & Salathe, M. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-11038-x · Cited by 27
Todd, J. L., Neely, M. L., Copeland, C., Frankel, C. W., Reynolds, J. M., & Palmer, S. M. (2018) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2018.10.006 · Cited by 28
“While controversy exists regarding the use of physiological endpoints in pulmonary trials(16, 17), it is notable that a precise understanding of the natural history of FVC in untreated patients with IPF was critical to enabling pivotal clinical trials employing FVC decline as the primary endpoint(18, 19).”
MethodIntegrative analyses of genes associated with idiopathic pulmonary fibrosis
Wang, H., Xie, Q., Ou‐Yang, W., & Zhang, M. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28153 · Cited by 29
“However, the prognosis of individual patients with IPF is hard to predict because no clinical biomarkers or parameters can reliably reflect disease progression.(5,6) In addition, individual differences play important roles in the efficacy of treatment of IPF.”
BackgroundThe Anti-Fibrotic Effects of CG-745, an HDAC Inhibitor, in Bleomycin and PHMG-Induced Mouse Models
Kim, Y.-S., Cha, H., Kim, H.-J., Cho, J.-M., & Kim, H.-R. (2019) · Molecules · doi:10.3390/molecules24152792 · Cited by 30
Glassberg, M. K., Nathan, S. D., Lin, C., Morgenthien, E. A., Stauffer, J. L., Chou, W., & Noble, P. W. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01052-y · Cited by 28
Self-citationBalestro, E., Cocconcelli, E., Giraudo, C., Polverosi, R., Biondini, D., Lacedonia, D., Bazzan, E., Mazzai, L., Rizzon, G., Lococo, S., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091469 · Cited by 26
“In our study population, antifibrotic therapy slowed down the rate of FVC decline; indeed, IPF patients under treatment lost, on average, approximately 100 mL/year of FVC, which mirrors what has been observed both in clinical trials [17,18] and in a number of real-world studies [19–21].”
ResultAntoniou, K. M., Kamekis, A., Symvoulakis, E. K., Kokosi, M. A., & Swigris, J. J. (2020) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000703 · Cited by 28
Self-citationUdwadia, Z. F., Pokhariyal, P. K., Tripathi, A. K. R., & Kohli, A. (2020) · Lung India · doi:10.4103/lungindia.lungindia_533_20 · Cited by 26
Current trends in candidate selection, contraindications, and indications for lung transplantation
Arjuna, A., Olson, M. T., & Walia, R. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-2021-09 · Cited by 35
Takahashi, T., Terada, Y., Pasque, M. K., Liu, J., Byers, D. E., Witt, C. A., Nava, R. G., Puri, V., Kozower, B. D., Meyers, B. F., et al. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.06.036 · Cited by 29
Suzuki, Y., Mori, K., Aono, Y., Kono, M., Hasegawa, H., Yokomura, K., Naoi, H., Hozumi, H., Karayama, M., Furuhashi, K., et al. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01587-3 · Cited by 27
Li, X., Yu, R., Wang, P., Wang, A., & Huang, H. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18147643 · Cited by 29
Inspiratory muscle training in interstitial lung disease: a systematic scoping review
Hoffman, M. (2021) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20210089 · Cited by 35
Nambiar, A. M., Walker, C. M., & Sparks, J. A. (2021) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666211039771 · Cited by 28
Mackintosh, J. A., Pietsch, M., Lutzky, V. P., Enever, D., Bancroft, S., Apte, S. H., Tan, M. E., Yerkovich, S. T., Dickinson, J. L., Pickett, H. A., et al. (2021) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2021-001127 · Cited by 32
Self-citationThe use of exhaled air analysis in discriminating interstitial lung diseases: a pilot study
Plantier, L., Smolinska, A., Fijten, R., Flamant, M., Dallinga, J. W., Mercadier, J.-J., Pachen, D. M. F. A., d’Ortho, M., van Schooten, F., Crestani, B., et al. (2022) · Respiratory Research · doi:10.1186/s12931-021-01923-5 · Cited by 29
Disparities in Rural Populations With Idiopathic Pulmonary Fibrosis
DeDent, A. M., Collard, H. R., & Thakur, N. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.03.042 · Cited by 26
Sanders, J. L., Axelsson, G. T., Putman, R. K., Menon, A. A., Dupuis, J., Xu, H., Wang, S., Murabito, J. M., Vasan, R. S., Araki, T., et al. (2022) · Thorax · doi:10.1136/thoraxjnl-2021-218315 · Cited by 25
Choi, B., Adan, N. M., Doyle, T. J., Estépar, R. S. J., Harmouche, R., Humphries, S. M., Moll, M. R., Cho, M. H., Putman, R. K., Hunninghake, G. M., et al. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.06.030 · Cited by 27
Achkar, M. A., Jamal, O., & Chaaban, T. A. (2022) · Annals of Thoracic Medicine · doi:10.4103/atm.atm_103_22 · Cited by 26
Wang, L., Shao, M., Jiang, W., & Huang, Y. (2022) · Tissue and Cell · doi:10.1016/j.tice.2022.101953 · Cited by 35
Knipe, R. S., Nurunnabi, M., Probst, C. K., Spinney, J. J., Abe, E. A., Bose, R. J., Ha, K., Logue, A., Nguyen, T. H., Servis, R. L., et al. (2023) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00086.2022 · Cited by 29
Effect of Antifibrotic Therapy on Survival in Patients With Idiopathic Pulmonary Fibrosis
de Andrade, J. A., Neely, M. L., Hellkamp, A. S., Culver, D. A., Kim, H. J., Liesching, T. N., Lobo, L. J., Ramaswamy, M., Safdar, Z., Bender, S. D., et al. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.03.003 · Cited by 29
Strategic outline of interventions targeting extracellular matrix for promoting healthy longevity
Park, J. Y. C., King, A., Björk, V., English, B. W., Fedintsev, A., & Ewald, C. Y. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00060.2023 · Cited by 33
Lung function trajectories in patients with idiopathic pulmonary fibrosis
Neely, M. L., Hellkamp, A. S., Bender, S. D., Todd, J. L., Liesching, T. N., Luckhardt, T., Oldham, J. M., Raj, R., White, E. S., & Palmer, S. M. (2023) · Respiratory Research · doi:10.1186/s12931-023-02503-5 · Cited by 31
Overview of Rheumatoid Arthritis-Associated Interstitial Lung Disease and Its Treatment
Pugashetti, J. V., & Lee, J. S. (2024) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0044-1782218 · Cited by 32
Nishimoto, T., Mlakar, L., Takihara, T., & Feghali‐Bostwick, C. A. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.07.039 · Cited by 25
Morell, F., Esser, D., Lim, J. T., Stowasser, S., Villacampa, A., Nieves, D., & Brosa, M. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0168-6 · Cited by 26
“It remains to be seen how recently reported findings in IPF [22–24] and the availability of new therapeutic options will change treatment patterns in IPF.”
Therapeutic advances in idiopathic pulmonary fibrosis
Fraser, E., & Hoyles, R. K. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-1-42 · Cited by 28
White, E. S., Borok, Z., Brown, K. M., Eickelberg, O., Günther, A., Jenkins, G. R., Kolb, M. R. J., Martínez, F. J., Roman, J., & Sime, P. J. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201602-0254st · Cited by 32
Advances in understanding the immunopathology of sarcoidosis and implications on therapy
Cinetto, F., & Agostini, C. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2016.1181541 · Cited by 26
Magnini, D., Montemurro, G., Iovene, B., Tagliaboschi, L., Gerardi, R. E., Greco, E. L., Bruni, T., Fabbrizzi, A., Lombardi, F., & Richeldi, L. (2017) · Respiration · doi:10.1159/000475780 · Cited by 26
Factors Promoting Development of Fibrosis in Crohn’s Disease
Rogler, G., & Hausmann, M. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00096 · Cited by 25
Yamakawa, H., Kitamura, H., Takemura, T., Ikeda, S., Sekine, A., Baba, T., Iwasawa, T., Hagiwara, E., Sato, S., & Ogura, T. (2018) · Respirology · doi:10.1111/resp.13313 · Cited by 24
Clinical Genetics in Interstitial Lung Disease
Newton, C. A., Molyneaux, P. L., & Oldham, J. M. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00116 · Cited by 29
Lambers, C., Boehm, P. M., Karabacak, Y., Samaha, E., Benazzo, A., Jaksch, P., & Roth, M. (2019) · BioMed Research International · doi:10.1155/2019/1345402 · Cited by 26
Hanta, İ., Çilli, A., & Sevinç, C. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00928-3 · Cited by 29
Kawamura, K., Ichikado, K., Ichiyasu, H., Anan, K., Yasuda, Y. U., Suga, M., & Sakagami, T. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0880-0 · Cited by 26
Lv, M., Liu, Y., Ma, S., & Yu, Z. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0111 · Cited by 28
A novel mechanoeffector role of fibroblast S100A4 in myofibroblast transdifferentiation and fibrosis
Southern, B. D., Li, H., Mao, H., Crish, J. F., Grove, L. M., Scheraga, R. G., Mansoor, S., Reinhardt, A., Abraham, S., Deshpande, G. M., et al. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105530 · Cited by 27
Shlobin, O. A., Shen, E., Wort, S. J., Piccari, L., Scandurra, J., Hassoun, P. M., Nikkho, S. M., & Nathan, S. D. (2024) · Pulmonary Circulation · doi:10.1002/pul2.12310 · Cited by 26
Self-citationde Mattos, W. L. L. D., Khalil, N., Spencer, L. G., Bonella, F., Folz, R. J., Rolf, J. D., Moğulkoç, N., LANCASTER, L. H., Jenkins, G. R., Lynch, D. A., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202310-1907oc · Cited by 27
Self-citationHoffman, E. T., Shah, A., Barboza, W. R., Rodríguez, L. R., Dherwani, R., Dooley, P. E., Minakin, K., Tomer, Y., Ayers, L. J., Jones, D. L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63735-1 · Cited by 48
Park, J., Lee, Y. J., Lee, J., Park, S. S., Cho, Y., Lee, S., Kim, Y. W., Han, S. K., & Yoo, C. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.346 · Cited by 24
McCarthy, C., Gallego, B. L., Trapnell, B. C., & McCormack, F. X. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-67144-4_24 · Cited by 27
Validity of the Patient Experiences and Satisfaction with Medications (PESaM) Questionnaire
PESaM Collaborating Group, Kimman, M., Wijsenbeek, M. S., van Kuijk, S. M. J., Wijnsma, K. L., van de Kar, N. C. A. J., Storm, M., van Jaarsveld, X., & Dirksen, C. D. (2018) · Patient · doi:10.1007/s40271-018-0340-6 · Cited by 26
Role of bone marrow mesenchymal stem cells in the development of PQ‑induced pulmonary fibrosis
Chen, J., Si, L., Zhou, L., & Deng, Y. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.9976 · Cited by 25
Chen, L., & Zhao, X. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214441 · Cited by 24
Maher, T. M., LANCASTER, L. H., Jouneau, S., Morrison, L. D., Lederer, D. J., Molina‐Molina, M., Bendstrup, E. M., Kirchgaessler, K.-U., Gilberg, F., Axmann, J., et al. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201810-720rl · Cited by 29
Self-citationYu, X., Yang, S.-G., Xie, Y., & Li, J. (2019) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2019.12.005 · Cited by 25
Metabolic Activation of Pirfenidone Mediated by Cytochrome P450s and Sulfotransferases
Zhou, S., Li, W., Li, W., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02073 · Cited by 24
Hisata, S., Bando, M., Homma, S. A., Kataoka, K., Ogura, T., Izumi, S., Sakamoto, S., Watanabe, K., Saito, Y., Shimizu, Y., et al. (2021) · Respiratory Investigation · doi:10.1016/j.resinv.2021.04.005 · Cited by 32
Automated Digital Quantification of Pulmonary Fibrosis in Human Histopathology Specimens
Testa, L. C., Julé, Y., Lundh, L., Bertotti, K., Merideth, M. A., O’Brien, K., Nathan, S. D., Venuto, D. C., El‐Chemaly, S., Malicdan, M. C. V., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.607720 · Cited by 28
“Pirfenidone and nintedanib are antifibrotic drugs approved by the Food and Drug Administration (FDA) as treatment for IPF, and lung transplantation may be performed in suitable candidates with severe disease (3, 4).”
BackgroundSelf-citationBallester, B., Milara, J., Montero, P., & Cortijo, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126502 · Cited by 26
E4 engages uPAR and enolase-1 and activates urokinase to exert antifibrotic effects
Sharma, S., Watanabe, T., Nishimoto, T., Takihara, T., Mlakar, L., Nguyen, X.-X., Sanderson, M., Su, Y., Chambers, R. A., & Feghali‐Bostwick, C. A. (2021) · JCI Insight · doi:10.1172/jci.insight.144935 · Cited by 25
Nintedanib vs pirfenidone in the management of COVID-19 lung fibrosis: A single-centre study
Singh, P. K., Behera, D., Gupta, S. S., Deep, A., Priyadarshini, S., & Padhan, P. (2022) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.1177/14782715221103402 · Cited by 27
Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone
Ma, H., Heiden, J. A. V., Uttarwar, S., Xi, Y., N’Diaye, E.-N., LaCanna, R., Caplazi, P., Gierke, S., Moffat, J. G., Wolters, P. J., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.00604-2022 · Cited by 30
Urteaga, M. B., Ruz, J. R., & González, M. S. (2022) · Radiología (English Edition) · doi:10.1016/j.rxeng.2022.10.009 · Cited by 40
Khor, Y. H., Schulte, M., Johannson, K. A., Marcoux, V. S., Fisher, J. H., Assayag, D., Manganas, H., Khalil, N., Kolb, M. R. J., Ryerson, C. J., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.02163-2022 · Cited by 25
Pulmonary Fibrosis Treated with Inhaled Interferon-gamma (IFN-γ)
Fusiak, T., Smaldone, G. C., & Condos, R. (2015) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2015.1221 · Cited by 23
Lin, C., Rezaee, F., Waasdorp, M., Shi, K., van der Poll, T., Borensztajn, K., & Spek, C. A. (2015) · Oncotarget · doi:10.18632/oncotarget.6095 · Cited by 27
The changing treatment landscape in idiopathic pulmonary fibrosis
Costabel, U. (2015) · European Respiratory Review · doi:10.1183/09059180.00011414 · Cited by 25
Iwasawa, T., Kanauchi, T., Hoshi, T., Ogura, T., Baba, T., Gotoh, T., & Oba, M. S. (2015) · Japanese Journal of Radiology · doi:10.1007/s11604-015-0496-0 · Cited by 26
Treatment of Idiopathic Pulmonary Fibrosis
Carlos, W. G., Strek, M. E., Wang, T. S., Patel, H., Raghu, G., Wilson, K. C., & Thomson, C. C. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201510-713cme · Cited by 25
Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis
Fukihara, J., & Kondoh, Y. (2016) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2016.1249854 · Cited by 27
Safety of nintedanib before lung transplant: an Italian case series
Balestro, E., Solidoro, P., Parigi, P., Boffini, M., Lucianetti, A., & Rea, F. (2018) · Respirology Case Reports · doi:10.1002/rcr2.312 · Cited by 25
Amifostine Analog, DRDE-30, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice
Arora, A., Bhuria, V., Hazari, P. P., Pathak, U., Mathur, S., Roy, B. G., Sandhir, R., Soni, R., Dwarakanath, B. S. R., & Bhatt, A. N. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00394 · Cited by 23
Effect of pirfenidone on wound healing in lung transplant patients
Mortensen, A., Cherrier, L., & Walia, R. (2018) · Multidisciplinary Respiratory Medicine · doi:10.1186/s40248-018-0129-4 · Cited by 27
Maldonado, M., Buendía-Roldán, I., Vicens‐Zygmunt, V., Planas‐Cerezales, L., Molina‐Molina, M., Selman, M., & Pardo, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0203779 · Cited by 24
Biondini, D., Balestro, E., Lacedonia, D., Cerri, S., Milaneschi, R., Luppi, F., Cocconcelli, E., Bazzan, E., Clini, E. M., Barbaro, M. P. F., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24303-4 · Cited by 25
Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study
Abe, M., Tsushima, K., Sakayori, M., Suzuki, K., Ikari, J., Terada, J., & Tatsumi, K. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s179427 · Cited by 25
Andersen, S., Axelsen, J. B., Ringgaard, S., Nyengaard, J. R., Nielsen, S. H., Genovese, F., Karsdal, M. A., Hyldebrandt, J. A., Sørensen, C. B., de Man, F. S., et al. (2019) · Pulmonary Circulation · doi:10.1177/2045894019848659 · Cited by 26
Pharmacological management of Idiopathic Pulmonary Fibrosis: current and emerging options
Trachalaki, A., Irfan, M., & Wells, A. U. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1822326 · Cited by 26
Interstitial lung disease: raising the index of suspicion in primary care
Zibrak, J. D., & Price, D. B. (2014) · npj Primary Care Respiratory Medicine · doi:10.1038/npjpcrm.2014.54 · Cited by 30
Kawano-Dourado, L. B., Kulkarni, T., Ryerson, C. J., Rivera‐Ortega, P., Baldi, B. G., Chaudhuri, N., Funke-Chambour, M., Hoffmann‐Vold, A., Johannson, K. A., Khor, Y. H., et al. (2024) · Thorax · doi:10.1136/thorax-2023-221148 · Cited by 28
Salisbury, M. L., Markin, C. R., Fadely, T. H., Guttentag, A. R., Humphries, S. M., Lynch, D. A., Kropski, J. A., & Blackwell, T. S. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202403-0524oc · Cited by 24
Loganath, K., Craig, N. J., Barton, A. K., Joshi, S. S., Anagnostopoulos, C., Erba, P. A., Glaudemans, A. W. J. M., Saraste, A., Bucerius, J. A., Lubberink, M., et al. (2024) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2024.102106 · Cited by 29
Myllärniemi, M., Tikkanen, J., Hulmi, J. J., Pasternack, A. H., Sutinen, E., Rönty, M. J., Leppäranta, O., Ma, H., Ritvos, O., & Koli, K. M. (2014) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-14-170 · Cited by 24
Jin, S., Ma, H., Liu, Z.-L., Fu, S., Zhang, C., & He, Y. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.11.013 · Cited by 25
Kreuter, M., Wälscher, J., & Behr, J. (2017) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000408 · Cited by 24
Gaffney, A. W., Steffie, W., Himmelstein, D. U., & McCormick, D. (2018) · BMC Health Services Research · doi:10.1186/s12913-018-3407-0 · Cited by 28
Zhang, E., Yang, Y., Zhang, J., Ding, G., Chen, S., Peng, C., Lavin, M. F., Yeo, A. J., Du, Z., & Shao, H. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7205 · Cited by 25
Troy, L. K., Grainge, C., Corte, T. J., Williamson, J., Vallely, M. P., Cooper, W. A., Mahar, A. M., Lai, S., Mulyadi, E., Torzillo, P. J., et al. (2019) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2019-000443 · Cited by 39
TRIM72 promotes alveolar epithelial cell membrane repair and ameliorates lung fibrosis
Cong, X., Nagre, N. N., Herrera, J., Pearson, A. C., Pepper, I., Morehouse, R., Ji, H., Jiang, D., Hubmayr, R. D., & Zhao, X. (2020) · Respiratory Research · doi:10.1186/s12931-020-01384-2 · Cited by 27
Kolonics-Farkas, A. M., Šterclová, M., Moğulkoç, N., Kuś, J., Hájková, M., Müller, V., Jovanović, D. M., Tekavec-Trkanjec, J., Littnerová, S., Hejduk, K., et al. (2020) · Drug Safety · doi:10.1007/s40264-020-00978-5 · Cited by 27
Changes in management of idiopathic pulmonary fibrosis: impact on disease severity and mortality
Hyldgaard, C., Møller, J., & Bendstrup, E. M. (2020) · European Clinical Respiratory Journal · doi:10.1080/20018525.2020.1807682 · Cited by 29
Feng, H., Zhao, Y., Li, Z., & Kang, J. (2020) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466620963015 · Cited by 28
Holland, A. E., Corte, T. J., Chambers, D. C., Palmer, A. J., Ekström, M. P., Glaspole, I., Goh, N. S. L., Hepworth, G., Khor, Y. H., Hoffman, M., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-040798 · Cited by 27
Self-citationSebastiani, M., Faverio, P., Manfredi, A., Cassone, G., Vacchi, C., Stainer, A., Pozzi, M. R., Salvarani, C., Pesci, A., & Luppi, F. (2020) · Biomedicines · doi:10.3390/biomedicines9010017 · Cited by 28
A mixed-methods pilot study of handheld fan for breathlessness in interstitial lung disease
Khor, Y. H., Saravanan, K., Holland, A. E., Lee, J. Y. T., Ryerson, C. J., McDonald, C. F., & Goh, N. S. L. (2021) · Scientific Reports · doi:10.1038/s41598-021-86326-8 · Cited by 35
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.